P/E ratio for ChemoCentryx (CCXI)
P/E ratio as of May 2024 (TTM): -27.5
According to ChemoCentryx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -27.5079. At the end of 2021 the company had a P/E ratio of -19.3.
P/E ratio history for ChemoCentryx from 2012 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -19.3 | -74.8% |
| 2020 | -76.4 | 87.49% |
| 2019 | -40.8 | 184.03% |
| 2018 | -14.4 | -189.27% |
| 2017 | 16.1 | -289.06% |
| 2016 | -8.51 | 13.41% |
| 2015 | -7.50 | 18.59% |
| 2014 | -6.32 | 3.76% |
| 2013 | -6.09 | -36.49% |
| 2012 | -9.60 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -138.69% | 🇺🇸 USA |
 Pfizer PFE | 15.1 | -154.74% | 🇺🇸 USA |
 AbbVie ABBV | 43.7 | -258.77% | 🇺🇸 USA |
 Amgen AMGN | 21.9 | -179.68% | 🇺🇸 USA |
 Biogen BIIB | 12.0 | -143.62% | 🇺🇸 USA |
 Merck MRK | 71.4 | -359.55% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -141.15% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.9 | -146.80% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -8.13 | -70.46% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.